Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Zidovudine plus interferon-[alpha] versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150x106/l: results of the Zidon trial

Fernández-Cruz, E., Lang, J-M, Jos Frissen, P.H., Furrier, V., Châateauvert, M., Boucher, C.A.B., Dowd, P., Stevens, J. and Mallal, S. (1995) Zidovudine plus interferon-[alpha] versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150x106/l: results of the Zidon trial. AIDS, 9 (9). pp. 1025-1035.

Link to Published Version: http://journals.lww.com/aidsonline/Abstract/1995/0...
*Subscription may be required

Abstract

Objective: To evaluate the efficacy and safety of zidovudine (ZDV) and lymphoblastoid interferon (IFN)-[alpha] combination therapy compared with ZDV monotherapy in HIV-infected subjects with CD4+ cell counts between 150 and 500x106/1.

Design: Open, randomized controlled trial with subjects stratified by the Centers for Disease Control and Prevention (CDC) 1986 classification of HIV disease (group 11/111 or IV). The study was amended to a sequential design in February 1992 to allow interim analyses to be conducted.

Setting: Outpatient clinics in 45 hospitals in Europe, Australia and Canada.

Participants: A total of 402 previously untreated subjects with symptomatic HIV infection (CDC group IV) and CD4+ count 150-500xT06/1 or asymptomatic HIV infection (CDC group 11/111) with CD4+ count 150-350 x 106/l.

Interventions: ZDV 250 mg twice daily with or without 3 MU subcutaneous injections of lymphoblastoid IFN-[alpha] three times per week.

Main outcome measures: Time to development of a study endpoint defined as: progression from CDC group 11/111 to group IV, group IV non-AIDS to AIDS, or group IV AIDS to a second AIDS-defining condition; also CD4+ count to < 50x 106/1 on two occasions at least 1 month apart or HIV-related death irrespective of CDC group on entry.

Results: There was no reduction in the rate of disease progression for patients receiving ZDV plus IFN-[alpha] compared with patients receiving ZDV alone. No major differences between the groups were seen for CD4+ counts or percentages, or p24 antigenaemia. In a subset of 70 patients, a similar proportion from both dose groups showed evidence of ZDV resistance after 48 weeks of treatment. More adverse experiences were seen in the ZDV/IFN-a group.

Conclusions: Combination therapy with low dose lymphoblastoid IFN-[alpha] and ZDV revealed no clinical benefit compared with ZDV monotherapy.

Item Type: Journal Article
Publisher: Lippincott Williams & Wilkins Ltd.
Copyright: (C) 1995 Lippincott-Raven Publishers
Notes: Simon Mallal appears as part of the Zidon Study Group
URI: http://researchrepository.murdoch.edu.au/id/eprint/15000
Item Control Page Item Control Page